Overview

Ceritinib is a selective oral inhibitor of the anaplastic lymphoma kinase (ALK), a targeted therapy for non-small cell lung cancer driven by ALK gene rearrangements. Compared with the first ALK inhibitor crizotinib, ceritinib shows greater ALK potency and improved activity against disease that has spread to the central nervous system. Correct patient selection is therefore central to getting the most from this agent.

Identifying the ALK-Positive Population

The essential step is confirmed ALK rearrangement by an approved diagnostic, because only tumors with this driver respond. ALK-positive NSCLC occurs in a distinct subgroup, often younger never-smokers, though testing—not demographics—should drive eligibility. Once identified, these patients can receive ceritinib in the first-line setting or after prior ALK-directed therapy, depending on regional labeling.

CNS Involvement and Prior ALK Inhibitor Exposure

Brain metastases are frequent in ALK-positive disease, and ceritinib's intracranial activity makes it relevant for patients with CNS involvement. For those who have already received crizotinib, ceritinib offers a next-generation option that retains ALK blockade while overcoming some crizotinib limitations. Prior exposure history, existing CNS disease, and performance status together shape sequencing decisions within the ALK inhibitor class.

Dosing, Tolerability and Sourcing

Ceritinib is supplied as 150 mg tablets, and dosing follows the approved schedule with attention to gastrointestinal tolerability. Procurement teams should track batch availability and storage conditions on the label, and plan for the continuous supply that oral targeted therapy requires. Clear cold-chain or room-temperature guidance from the supplier supports safe handling through distribution.

Food Effect and Dosing Flexibility

Like other ALK inhibitors, ceritinib's tolerability can be managed through dosing strategy, including whether it is taken with food, under the guidance of the prescriber and the approved label. Gastrointestinal effects are the most common reason for dose interruption, so anticipating supportive care and clear patient instructions improves adherence and protects the treatment course. From a procurement angle, this variability means demand is not perfectly predictable: some patients stay on therapy longer, while others require careful re-titration after a pause. Maintaining buffer stock, monitoring expiry closely, and keeping open communication with the prescribing team help ensure continuity when individual dosing plans shift.

FAQ

Q: Who should be tested for ceritinib eligibility? A: Any advanced NSCLC patient should have ALK rearrangement confirmed with an approved test before ALK inhibitor therapy.

Q: Why does ceritinib matter for brain metastases? A: It shows meaningful intracranial activity, addressing a common and difficult site of ALK-positive disease spread.

Q: Can ceritinib follow crizotinib? A: Yes, it is used in patients who have received prior ALK-directed therapy, subject to local approvals and labeling.

Q: How is ceritinib supplied? A: It is provided as 150 mg tablets, stored and handled per the approved product label.